Current and future treatments of autoimmune hepatitis

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 3, 2009, Pages 269-291

  Czaja, Albert J ^a  

^a Mayo Clinic   (United States)

Author keywords

Calcineurin inhibitor; Corticosteroid; Future therapy; Purine antagonist

Indexed keywords

ALLOPURINOL; ANTIBODY; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUDESONIDE; CALCINEURIN INHIBITOR; CALCIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DEFLAZACORT; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LIVER ANTIGEN; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; PURINE ANTAGONIST; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THIOGUANINE DERIVATIVE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VITAMIN D;

ADOPTIVE TRANSFER; ALOPECIA; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; AUTOIMMUNE HEPATITIS; BONE MARROW SUPPRESSION; CLINICAL PROTOCOL; CLINICAL TRIAL; CYTOPENIA; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELDERLY CARE; ESOPHAGUS VARICES BLEEDING; FIRST PASS EFFECT; HEPATITIS A; HEPATITIS B; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; LYMPHOCYTOPENIA; MESENCHYMAL STEM CELL TRANSPLANTATION; NAUSEA; NONHUMAN; PANCREATITIS; PREGNANCY; REGULATORY T LYMPHOCYTE; RELAPSE; REVIEW; SALVAGE THERAPY; SCORING SYSTEM; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VOMITING; DOSE RESPONSE; DRUG COMBINATION;

ADRENAL CORTEX HORMONES; AZATHIOPRINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PREDNISONE;

EID: 68149089466     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.15     Document Type: Review

References (242)

1. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q. J. Med. 40, 159-185 (1971).
2. Soloway RD, Summerskill WHJ, Baggenstoss AH et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 63, 820-833 (1972).
3. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1, 735-737 (1973).
4. Floreani A, Niro G, Rosa Rizzotto E et al. Type 1 autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment. Pharmacol. Ther. 24(7), 1051-1057 (2006).
5. Seo S, Toutounjian R, Conrad A, Blatt L, Tong MJ. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J. Gastroenterol. Hepatol. 23, 1410-1414 (2008).
6. Roberts SK, Therneau T, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 110, 848-857 (1996).
7. Schvarcz R, Glaumann H, Weiland O. Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis. J. Hepatol. 18, 15-23 (1993).
8. Dufour J-F, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann. Intern. Med. 127, 981-985 (1997).
9. Cotler SJ, Jakate S, Jensen DM. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J. Clin, Gastroenterol. 32, 428-430 (2001).
10. Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 39, 1631-1638 (2004).
11. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J. Hepatol. 40, 644-650 (2004).
12. Mohamadnejad M, Malekzadeh R, Nasseri-Maghaddam S et al. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig. Dis. Sci. 50, 547-551 (2005).
13. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 4, 622-627 (1984).
14. Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin. Drug Saf. 7(3), 319-333 (2008).
15. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value, of the model of end stage liver disease. Hepatology 46, 1138-1145 (2007).
16. Czaja AJ, Ammon HV, Summerskill WHJ. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 78, 518-523 (1980).
17. Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A. Corticosteroid-treated chronic active hepatitis in remission. Uncertain prognosis of chronic persistent hepatitis. N. Engl. J. Med. 304, 5-9 (1981).
18. Czaja AJ, Menon KVN, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 35, 890-897 (2002).
19. Hegarty JE, Nouri-Aria KT, Portmann B, Eddleston ALWF, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 3, 685-689 (1983).
20. Stellon AJ, Keating JJ, Johnson PJ, MacFarlane IG, Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 8, 781-784(1988).
21. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N. Engl. J. Med. 333, 958-963 (1995).
22. Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J. Hepatol. DO1: 10.1016/j.jhep.2009.02.026 (2009).
23. Czaja AJ, Beaver SJ, Shiels MT. Sustained remission following corcicosteroid therapy of severe HBsAg-negative chronic active hepatitis. Gastroenterology 92, 215-219 (1987).
24. Montano-Loza A, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int. 27, 507-515 (2007).
25. Czaja AJ. Progress in the diagnosis and treatment of autoimmune hepatitis. Minerva Med. 99(6), 549-568 (2008).
26. Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and non-Caucasians. Sem. Liver Dis. (In Press) (2009).
27. Montano-Loza AJ, Carpenter HA, Czaja AJ. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am. J. Gastroenterol. 103, 1944-1951 (2008).
28. Yeoman AD, Al-Chalabi T, Karani JB et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 48, 863-870 (2008).
29. Czaja AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl. 8, 505-513 (2002).
30. Vierling JM, Flores PA. Evolving new therapies of autoimmune hepatitis. Clin. Liver Dis. 6, 825-850 (2002).
31. Czaja AJ. Emerging treatments for autoimmune hepatitis. Curr. Drug Targets Inflamm. Allergy 1, 317-326 (2002).
32. Czaja AJ. Treatment of autoimmune hepatitis. Sem. Liver Dis. 22, 365-377 (2002).
33. Czaja AJ. Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. Minerva Gastroenterol. Dietol. 53, 43-78 (2007).
34. Czaja AJ, Bayraktar Y. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J. Gastroenterol. (In Press) (2009).
35. Czaja AJ, Bianchi FB, Carpenter HA et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 41, 207-215 (2005).
36. Schalm SW, Korman MG, Summerskill WH, Czaja AJ, Baggenstoss AH. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am. J. Dig. Dis. 22, 973-980 (1977).
37. Baggenstoss AH, Soloway RD, Summerskill WHJ, Elveback LR, Schoenfield LJ. Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum. Pathol. 3, 183-198 (1972).
38. Cooksley WGE, Bradbear RA, Robinson W et al. The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis. Hepatology 6, 345-348 (1986).
39. Czaja AJ, Taswell HF, Rakela J, Schimek C. Frequency of antibody to hepatitis C virus in asymptomatic HBsAg negative chronic active hepatitis. J. Hepatol. 14, 88-93 (1992).
40. Czaja AJ, Magrin S, Fabiano C et al. Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. Dig. Dis. Sci. 40, 33-40 (1995).
41. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 42, 53-62 (2005).
42. Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent onset autoimmune hepatitis: biopsy findings and clinical correlations. Am. J. Surg. Path. 19, 699-708 (1995).
43. Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated HBsAg-negative chronic active hepatitis. Gastroenterology 87, 1222-1227 (1984).
44. Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis. A study of 68 patients. J. Clin. Gastroenterol. 35, 75-81 (2002).
45. Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. DOI: 10.1111/j.1478-3231.2008:01904.x (2008).
46. Manns MP, Bahr MJ, Woynarowski M et al. Budesonide 3 mg TID is superior to prednisolone in combination with azathioprine in the treatment of autoimmune hepatitis (abstract). J. Hepatol. 48(Suppl. 2), S369 (2008).
47. Uribe M, Go VLW, Kluge D. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects. J. Clin. Gastroenterol. 6, 331-335 (1984).
48. Summerskill WHJ, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 16, 876-883 (1975).
49. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 36, 479-497 (2002).
50. Czaja AJ. Treatment strategies in autoimmune hepatitis. Clin. Liver Dis. 6, 799-824 (2002).
51. Montano Loza AJ, Czaja AJ. Current therapy for autoimmune hepatitis. Nature Clin. Pract. Gastroenterol. Hepatol. 4, 202-214 (2007).
52. Kanzler S, Lohr H, Gerken G, Galle PR, Lohse AW. Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience. Z. Gastroenterol. 39, 339-341 (2001).
53. Kanzler S, Gerken G, Lohr H, Galle PR, Meyer zum Buschenfelde KH, Lohse AW. Duration of immunosuppressive therapy in autoimmune hepatitis. J. Hepatol. 34, 354-355 (2001).
54. Montano-Loza A, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am. J. Gastroenterol. 102, 1005-1012 (2007).
55. Schalm SW, Summerskill WHJ, Go VLW. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone. Gastroenterology 72, 910-913 (1977).
56. De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J. Neuroimmunol. 109, 16-22 (2000).
57. Almawi WY. Molecular mechanisms of glucocorticoid effects. Mod. Asp. Immunobiol. 2, 71-82 (2001).
58. Chan GLC, Erdmann GR, Gruber SA, Matas AJ, Canafax DM. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J. Clin. Pharmacol. 30, 358-363 (1990).
59. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol. 43., 329-339 (1992).
60. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate Am. J. Gastroenterol. 91, 423-433 (1996).
61. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab. Dispos. 29, 601-605 (2001).
62. Thomas CW, Myhre GM, Tschumper R et al. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J. Pharmacol. Exp. Ther. 312, 537-545 (2005).
63. + T lymphocytes. J. Clin. Invest. 111, 1133-1145 (2003).
64. Atreya I, Neurath MF. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications. Expert Rev. Gastroenterol. Hepatol. 2, 23-34 (2008).
65. Lewis GP, Jusko WJ, Burke CW, Graves L. Prednisone side-effects and serum protein levels: a collaborative study. Lancet 2, 778-781 (1971).
66. Uribe M, Go VLW. Corticosteroid pharmacokinetics in liver disease. Clin. Pharmacokinet. 4, 233-240 (1979).
67. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch. Dermatol. 131, 193-197 (1995).
68. Otterness D, Szumlanski C, Lennard L et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin. Pharmacol. Ther. 62, 60-73 (1997).
69. Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126, 608-614 (1997).
70. Alves S, Prata MJ, Ferreira F, Amorim A. Screening of thiopurine methyl S-transferase mutations by horizontal conformation-sensitive gel electrophoresis. Hum. Mutat. 15, 246-253 (2000).
71. Black AJ, McLeod HL, Capell HA et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann. Intern. Med. 129, 716-718 (1998).
72. Cuffari C, Dassopoulis T, Turnbough L, Thompson RE, Bayless TM. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2, 410-417 (2004).
73. McLeod HL, Relling MV, Liu Q, Pui C-H, Evans WE. Polymorphic thiopurine methyl transferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 85, 1897-1902 (1995).
74. Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig. Dis. Sci. 51, 968-975 (2006).
75. Bacon BR, Treuhaft WH, Goodman AM. Azathioprine-induced pancytopenia. Occurrence in two patients with connective tissue diseases. Arch. Intern. Med. 141, 223-226 (1981).
76. Maddocks JL, Lennard L, Amess J, Amor R, Meyrick TR. Azathioprine and severe bone marrow depression. Lancet 1, 156 (1986).
77. Ben Ari Ziv, Mehta A, Lennard L, Burroughs AK. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J. Hepatol. 23, 351-354 (1995).
78. Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J. Hepatol. 7, 441-447 (2002).
79. Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J. Hepatol. 45, 584-591 (2006).
80. deBoer NKH, DeGraaf P, Wilhelm AJ, Mulder CJJ, Van Bodegraven AA. On the limitation of 6-thioguaninenucleotide monitoring during tioguanine treatment. Aliment. Pharmacol. Ther. 22, 447-451 (2005).
81. Lowry PW, Franklin CL, Weaver AL et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 40, 665-670 (2001).
82. Stellon AJ, Davies A, Compston J, Williams R. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy. Gastroenterology 89, 1078-1083 (1985).
83. Hay JE, Guichelaar MM. Evaluation and management of osteoporosis in liver disease. Clin. Liver Dis. 9, 747-766 (2005).
84. Sanchez AJ, Aranda-Michel J. Liver disease and osteoporosis. Nutr. Clin. Pract. 21, 273-278 (2006).
85. Collier J. Bone disorders in chronic liver disease. Hepatology 46, 1271-1278 (2007).
86. Worns MA, Teufel A, Kanzler S et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am. J. Gastroenterol. 103, 138-146 (2008).
87. Bellot P, Garcia-Pagan JC, Abraldes JG, Bosch J. Primary prophylaxis of esophageal bleeding in cirrhosis. Gastroenterol. Clin. Biol. 32, 532-540 (2008).
88. Czaja AJ, Wolf AM, Summerskill WHJ. Development and early prognosis of esophageal varices in severe chronic active liver disease (CALD) treated with, prednisone. Gastroenterology 77, 629-633 (1979).
89. Czaja AJ, Dos Santos RM, Porto A, Santrach PJ, Moore SB. Immune phenotype of chronic liver disease. Dig. Dis. Sci. 43, 2149-2155 (1998).
90. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576 (2007).
91. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134, 1752-1763 (2008).
92. Miyake Y, Iwasaki Y, Terada R et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J. Hepatol. 43, 951-957 (2005).
93. Verma S, Gunuwan B, Mendler M et al. Factors predicting relapse and poor outcome in type 1 autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am. J. Gastroenterol. 99, 1510-1516 (2004).
94. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 43, 532-538 (2006).
95. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 105, 1502-1507 (1993).
96. Czaja AJ, Strettell MDJ, Thomson LJ et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 25, 317-323 (1997).
97. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RAF, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatalogy 15, 215-221 (1992).
98. Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease (CALD): correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 80, 687-692 (1981).
99. Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int. 23, 116-123 (2003).
100. Luth S, Herkel J, Kanzler S et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J. Clin. Gastroenterol. 42, 926-930 (2008).
101. Runyon BA. Exquisite sensitivity to small decrements in corticosteroid dose in autoimmune chronic active hepatitis. J. Clin. Gastroenterol. 9, 541-542 (1987).
102. Czaja AJ. Low dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 11, 1044-1049 (1990).
103. Seela S, Sheela H, Boyer JL. Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int. 25, 734-739 (2005).
104. Al-Chalabi T, Underhill JA, Portmann BC et al. Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome. Clin. Gastroenterol. Hepatol. 6, 1389-1395 (2008).
105. Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J. Clin. Gastroenterol. 39, 819-825 (2005).
106. Schalm SW, Ammon HV, Summerskill WHJ. Failure of customary treatment in chronic active liver disease: causes and management. Ann. Clin. Res. 8, 221-227 (1976).
107. Schramm C, Kanzler S, Meyer zum Buschenfelde K-H, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am. J. Gastroenterol. 96, 1587-1591 (2001).
108. Verslype C, George C, Buchel E, Nevens F, Van Steenbergen W, Fevery J. Diagnosis and treatment of autoimmune hepatitis at age 65 and older. Aliment. Pharmacol. Ther. 21, 695-699 (2005).
109. Granito A, Muratori L, Pappas G et al. Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Aliment. Pharmacol. Ther. 21, 1273-1277 (2005).
110. Miyake T, Miyaoka H, Abe M et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol. Res. 36, 139-142 (2006).
111. Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral center. J. Hepatol. 45, 575-583 (2006).
112. Czaja AJ. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging 25, 219-239 (2008).
113. Lebovics E, Schaffner F, Klion EM, Simon C. Autoimmune chronic active hepatitis in postmenopausal women. Dig. Dis. Sci. 30, 824-828 (1985).
114. Wang KK, Czaja AJ. Prognosis of corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis in postmenopausal women: a retrospective analysis. Gastroenterology 97, 1288-1293 (1989).
115. Heneghan MA, Norris SM, O'Grady JG, Harrison PM, McFarlane IG. Management and outcome of pregnancy in autoimmune hepatitis. Gut 48, 97-102 (2001).
116. Candia L, Marquez J, Espinoza LR. Autoimmune hepatitis and pregnancy: a rheumatologist's dilemma. Semin. Arthritis Rheum. 35, 49-56 (2005).
117. Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse AW. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am. J. Gastroenterol: 101, 556-560 (2006).
118. Uribe M, Chavez-Tapia NC, Mendez-Sanchez N. Pregnancy and autoimmune hepatitis. Ann. Hepatol. 5, 187-189 (2006).
119. Werner M, Bjornsson E, Prytz H et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand. J. Gastroenterol. 42, 986-91 (2007).
120. Varma RR, Michelsohn NH, Borkowf HI, Lewis JD. Pregnancy in cirrhotic and noncirrhotic portal hypertension. Obstet. Gynecol. 50, 217-222 (1977).
121. Rosenkrantz JG, Githens JH, Cox SM, Kellum DL. Azathioprine (Imuran) and pregnancy. Am. J. Obstet. Gynecol. 97 387-394 (1967).
122. De Boer NK, Jarbandhan SV, de Graaf P, Mulder CJ, van Elburg RM, van Bodegraven AA. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am. J. Gastroenterol. 101, 1390-1392 (2006).
123. Buchel E, Van Steenbergen W, Nevens F, Fevery J. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am. J. Gastroenterol. 97, 3160-3165 (2002).
124. Whitacre CC, Reingold SC, O'Looney PA. A gender gap in autoimmunity. Science 283, 1277-1278 (1999).
125. Baeres M, Herkel J, Czaja AJ et al. Establishment of standardized SLA/LP. immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 51, 259-264 (2002).
126. Czaja AJ. Autoantibodies in autoimmune liver disease. Adv. Clin. Chem. 40, 127-164 (2005).
127. Ma Y, Okamoto M, Thomas MG et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 35, 658-664 (2002).
128. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/ liver pancreas and HLA risk factors in type 1 autoimmune hepatitis. Am. J. Gastroenterol. 413-419 (2002).
129. Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity 35, 475-483 (2002).
130. Porta G, Da Costa Gayotto LC, Alvarez F. Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure. J. Ped. Gastroenterol. Nutr. 11, 138-140 (1990).
131. Maggiore G, Porta G, Bernard O et al. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J. Pediatr. 116, 280-282 (1990).
132. Herzog D, Rasquin-Weber AM, Debray D, Alvarez F. Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. J. Hepatol. 27, 578-582 (1997).
133. Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin. Gastroenterol. Hepatol. 2, 625-631 (2004).
134. Miyake Y, Iwasaki Y, Terada R et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment. Pharmacol. Ther. 23, 1347-1353 (2006).
135. Viruet EJ, Torres EA. Steroid treatment in fulminant hepatic failure secondary to autoimmune hepatitis. P. R. Health Sci. J. 17, 297-300 (1998).
136. Ichai P, Duclos-Vallee J-C, Guettier C et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 13, 996-1003 (2007).
137. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 95, 448-453 (1988).
138. Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation (editorial). Liver Transpl. 13, 953-955 (2007).
139. Bajaj JS, Saeian K, Varma RR et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared with autoimmune hepatitis: a tertiary referral center experience. Am. J. Gastroenterol. 100, 1121-1125 (2005).
140. Penn I. Tumor incidence in human allograft recipients. Transplant. Proc. 11, 1047-1051 (1979).
141. Wang KK, Czaja AJ, Beaver SJ, Go VLW. Extrahepatic malignancy following, long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology 10, 39-43 (1989).
142. Person JL, McHutchison JG, Fong TL, Redeker AG. A case of cyclosporine-sensitive, steroid resistant, autoimmune chronic active hepatitis. J. Clin. Gastroenterol. 17, 317-320 (1993).
143. Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type 1 autoimmune chronic active hepatitis. J. Hepatol. 21, 1040-1047 (1994).
144. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am. J. Gastroenterol. 94, 241-248 (1999).
145. Malekzadeh R, Nasser-Moghaddam S, Kaviani M-J, Taheri H, Kamalian N, Sotoudeh M. Cyclosporin-A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig. Dis. Sci. 46, 1321-1327 (2001).
146. Van Thiel DH, Wright H, Carroll P et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am. J. Gastroenterol. 90, 771-776 (1995).
147. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J. Clin. Gastroenterol. 38, 805-809 (2004).
148. Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J. Gastroenterol. 13, 3232-3236 (2007).
149. Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 110, 271-274 (1996).
150. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis patients resistant to or intolerant of azathioprine. J. Hepatol. 33, 371-375 (2000).
151. Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can. J. Gastroenterol. 18, 321-326 (2004).
152. Chatur N, Ramji A, Bain VG et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian Association for the Study of Liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int. 25, 723-727 (2005).
153. Inductivo-Yu I, Adams A, Gish RG et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin. Gastroenterol. Hepatol. 5, 799-802 (2007).
154. Hlivko JT, Shiffman ML, Stravitz RT et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin. Gastroenterol. Hepatol. 6, 1036-1040 (2008).
155. Hennes EM, Oo YH, Schramm C et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am. J. Gastroenterol. 103, 3063-3070 (2008).
156. Wolf DC, Bojito L, Facciuto M, Lebovics E. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience. Dig. Dis. Sci. DOI: 10.1007/s10620-008-0632-0.
157. Heneghan MA, Al-Chalabi T, McFarlane IG. Cost-effectiveness of pharmacotherapy for autoimmune hepatitis. Expert Opin. Pharmacother. 7, 145-156 (2006).
158. Czaja AJ. Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree (editorial). J. Hepatol. (2009).
159. Clissold SP, Heel RC. Budesonide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 28, 485-518 (1984).
160. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment. Pharmacol. Ther. 8, 585-590 (1994).
161. Geier A, Gartung C, Dietrich CG, Wasmuth HE, Reinartz P, Matern S. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J. Gastroenterol. 9, 2681-2685 (2003).
162. Wiegand J, Schuller A, Kanzler S et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int. 25, 927-934 (2005).
163. Zandieh I, Krygier D, Wong V et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can. J. Gastroenterol. 22, 388-392 (2008).
164. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 119, 1312-1316 (2000).
165. Kanzler S, Gerken G, Dienes HP, Meyer zum Buschenfelde KH, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis - report of three cases. Z. Gastroenterol. 35, 571-578 (1997).
166. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J. Hepatol. 29, 990-993 (1998).
167. Kerkar N, Dugan C, Rumbo C et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am. J. Transplant. 5, 1085-1089 (2005).
168. Santos ES, Arosemena LR, Raez LE, O'Brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of the literature. Liver Int. 26, 625-629 (2006).
169. Carmassi F, Morale R, Puccetti R et al. Efficacy of intravenous immunoglobulin therapy in a case of autoimmune-mediated chronic active hepatitis. Clin. Exp. Rheumatol. 10, 13-17 (1992).
170. Rebollo Bernardez J, Cifuentes Mimoso C, Pinar Moreno A et al. Deflazacort for long-term maintenance of remission in type 1 autoimmune hepatitis. Rev. Esp. Enferm. Dig. 91, 630-638 (1999).
171. Nakamura K, Yoneda M, Yokohama S et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J. Gastroenterol. Hepatol. 13, 490-495 (1998).
172. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 30, 1381-1386 (1999).
173. de Boer NKH, van Nieuwkerk CMJ, Pages MNA, de Boer SY, Derijks LJJ, Mulder CJJ. Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. Eur. J. Gastroenterol. 17, 457-461 (2005).
174. de Boer NKH, De Graaf P, Wilhelm AJ, Mulder CJJ, Van Bodegraven AA. On the limitation of 6-thioguaninenucleotide monitoring during thioguanine treatment. Aliment. Pharmacol. Ther. 22, 447-451 (2005).
175. Chase WF, Winn RE, Mayes GR. Oral pulse prednisone therapy in the treatment of HBsAg negative chronic active hepatitis. Gastroenterology 83, 1292-1296 (1982).
176. Czaja AJ, Wang KK, Shiels MT, Katzmann JA. Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. A prospective randomized treatment trial evaluating clinical, biochemical, and lymphocyte, subset responses. J. Hepatol, 17, 180-186 (1993).
177. Cross TJS, Antoniades CG, Muieson P et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl. 13, 1382-1388 (2007).
178. Ahmed M, Mutimer D, Hathaway M, Hubscher S, McMaster P, Elias E. Liver transplantation for autoimmune hepatitis: a 12-year experience. Transpl. Proc. 29, 496 (1997).
179. Ratziu V, Samuel D, Sebagh M et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J. Hepatol. 30, 131-141 (1999).
180. Reich DJ, Fiel I, Guarrera JV et al. Liver transplantation for autoimmune hepatitis. Hepatology 32, 693-700 (2000).
181. Neuberger J. Transplantation for autoimmune hepatitis. Semin. Liver Dis. 22, 379-385 (2002).
182. Vogel A, Heinrich E, Bahr MJ et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin. Transplant. 18, 62-69 (2004).
183. Khalaf H, Mourad W, El-Sheikh Y et al. Liver transplantation for autoimmune hepatitis: a single-center experience. Transplant. Proc. 39, 1166-1170 (2007).
184. Campsen J, Zimmerman MA, Trotter JF et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl. 14, 1281-1286 (2008).
185. Wiesner RH, Demetris AJ, Belle SH et al. Acute allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 28, 638-645 (1998).
186. Seaberg EC, Belle SH, Beringer KC, Schivins JL, Detre KM. Liver transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS liver transplant registry. In: Clinical Transplants 1998. Cecka JM, Terasaki PI (Eds). UCLA Tissue Typing Laboratories, CA, USA, 17-37 (1999).
187. Neuberger J, Portmann B, Calne R, Williams R. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation 37, 363-365 (1984).
188. Devlin J, Donaldson P, Portmann B, Heaton N, Tan K-C, Williams R. Recurrence of autoimmune hepatitis following liver transplantation. Liver Transpl. Surg. 1, 162-165 (1995).
189. Gotz G, Neuhaus R, Bechstein WO et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplant. Proc. 31, 430-431 (1999).
190. Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 68, 253-256 (1999).
191. Gonazalez-Koch A, Czaja AJ, Carpenter HA et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl. 7, 302-310 (2001).
192. Kerkar N, Hadzic N, Davies ET et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 351, 409-413 (1998).
193. Jones DEJ, James OFW, Portmann B, Burt AD, Williams R, Hudson M. Development of autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Hepatology 30, 53-57 (1999).
194. Gupta P, Hart J, Millis JM, Cronin D, Brady L. De novo hepatitis with autoimmune antibodies and atypical histology. A rare cause of late graft dysfunction after pediatric liver transplantation. Transplantation 71, 664-668 (2001).
195. Heneghan MA, Portmann BC, Norris SM et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 34, 464-470 (2001).
196. Spada M, Bertani A, Sonzogni A et al. A cause of late graft dysfunction after liver transplantation in children: de novo autoimmune hepatitis. Transplant. Proc. 33, 1747-1748 (2001).
197. Salcedo M, Vaquero J, Banares R et al. Response to steroids in de novo autoimmune hepatitis after transplantation. Hepatology 35, 349-356 (2002).
198. Keaveny AP, Gordon FD, Khettry U. Post-liver transplantation de novo hepatitis with overlap features. Pathol. Int. 55, 660-664 (2005).
199. Rodriguez-Diaz Y, Reyes-Rodriguez R, Dorta-Francisco MC et al. De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Transplant. Proc. 38, 1467-1470 (2006).
200. Huguet S, Vinh J, Johanet C et al. Identification by proteomic tool of atypical anti-liver/kidney microsome autoantibodies targets in de novo autoimmune hepatitis after liver transplantation. Ann. NY Acad. Sci. 1109, 345-357 (2007).
201. Venick RS, McDiarmid SV, Farmer DG et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am. J. Transpl. 7, 955-963 (2007).
202. Lefkowitch JH. Diagnostic issues in transplantation pathology. Clin. Liver Dis. 6, 555-570 (2002).
203. Demetris AJ, Adeyi O, Bellamy CO et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 44, 489-501 (2006).
204. Fiel MI, Agarwal K, Stanca C et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl. 14, 861-871 (2008).
205. Demetris AJ, Sebagh M. Plasma cell hepatitis in liver allografts: variant of rejection or autoimmune hepatitis? (editorial). Liver Transpl. 14, 750-755 (2008).
206. Krasinskas AM, Demetris AJ, Poterucha JJ, Abraham SC. The prevalence and natural history of untreated isolated central perivenulitis in adult allograft livers. Liver Transpl. 14, 625-632 (2008).
207. Hayashi M, Keefe EB, Krams SM et al. Allograft rejection after liver transplantation for autoimmune liver disease. Liver Transplant. Surg. 4, 208-214 (1998).
208. Czaja AJ. The immunoreactive propensity of autoimmune hepatitis: is it corticosteroid dependent after liver transplantation? (editorial). Liver Transplant. Surg. 5, 4S0-463 (1999).
209. Trouillot TE, Shrestha R, Kam I, Wachs M, Everson GT. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. Liver Transpl. Surg. 5, 375-380 (1999).
210. Czaja AJ. Autoimmune hepatitis - part A: pathogenesis. Expert Rev. Gastroenterol. Hepatol. 1(1), 113-128 (2007).
211. Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: xenoimmunization with human antigens. Hepatology 39, 1066-1074 (2004).
212. Christen U, Holdener M, Hintermann E. Animal models of autoimmune hepatitis. Autoimmun. Rev. 6, 306-311 (2007).
213. Holdener M, Hintermann E, Bayer M et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J. Exp. Med. 205, 1409-1422 (2008).
214. Bowen DG. Of mice and molecular mimicry: modeling autoimmune hepatitis. Hepatology 48, 1013-1015 (2008).
215. Kyriakou DS, Alexandrakis MG, Zachou K, Passam F, Stathakis NE, Dalekos GN. Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J. Hepatol. 39, 679-685 (2003).
216. Tsikrikoni A, Kyriakou DS, Rigopoulou EI et al. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J. Hepatol. 42, 393-399 (2005).
217. Zachou K, Rigopoulou EI, Tsikrikoni A et al. Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production. J. Autoimmun. 25, 283-288 (2005).
218. Tsikrikoni A, Rigopoulou EI, Zachou K, Liaskos C, Kyriakou D, Dalekos GN. Bone marrow findings in patients with autoimmune liver diseases. J. Gastroenterol. Hepatol. 23(8 Pt 2), e416-e421 (2008).
219. Kuo TK, Hung S-P, Chuang C-H et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology 134 2111-2121 (2008).
220. + regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J. Autoimmun. 25, 63-71 (2005).
221. + regulatory T cells in health and autoimmune hepatitis. J. Immunol. 176, 4484-4491 (2006).
222. Hirschfield GM, Heathcote J. T regulatory cells and autoimmune liver disease (editorial). Liver Int. 28, 155-157 (2008).
223. Longhi MS, Meda F, Wang P et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 47, 581-591 (2008).
224. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot study of interferon nonresponders. Gastroenterology 118, 655-660 (2000).
225. Schreiber S, Fedorak RN, Nielsen OH et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 119, 1461-1472 (2000).
226. Rutgeerts P, D'Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117, 761-769 (1999).
227. Naveau S, Chollet-Martin S, Dharancy S et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 39, 1390-1397 (2004).
228. Boetticher NC, Peine CJ, Kwo P et al. A randomized, double-blinded, placebo-controlled mulicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 135, 1953-1960 (2008).
229. Tobon GJ, Canas C, Jaller J-J, Restrepo J-C, Anaya J-M. Serious liver disease induced by infliximab. Clin. Rheumatol. 26, 578-581 (2007).
230. Geramno V, Picchianti Diamanti A, Baccano G et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann. Rheum. Dis. 64, 1519-1520 (2005).
231. Hannon GJ. RNA interference. Nature 418, 244-251 (2002).
232. Davidson BL. Hepatic diseases - hitting the target with inhibitory RNAs. N. Engl. J. Med. 349, 2357-2359 (2003).
233. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 431, 371-378 (2004).
234. McCafferty AP, Nakai H, Pandey K et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol. 21, 639-644 (2003).
235. Song E, Lee S-K, Wang J et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9, 347-351 (2003).
236. Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL. Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones. Proc. Natl. Acad. Sci. USA 95, 12528-12531 (1998).
237. Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL. Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses. Hum. Immunol. 61, 640-650 (2000).
238. Schwartz RS. The new immunology - the end of immunosuppressive drug therapy (editorial)? N Engl. J. Med. 340, 1754-1756 (1999).
239. Guinan EC, Boussiotis VA, Neuberg D et al. Transplantation of anergic histoincompatible bone marrow allografts. N. Eng. J. Med. 340, 1704-1714 (1999).
240. Wardrop RM, Whitacre CC. Oral tolerance in the treatment of inflammatory autoimmune diseases. Inflamm. Res. 48, 106-119 (1999).
241. Nagler A, Pines M, Abadi U et al. Oral tolerization ameliorates liver disorders associated with chrome graft versus host disease in mice. Hepatology 31, 641-648 (2000).
242. Lohse AW, Dienes HP, Meyer zum Buschenfelde K-H. Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression. Hepatology 27, 1536-1543 (1998).